Patents Examined by D. L. Jones
  • Patent number: 12036234
    Abstract: Disclosed are heparin conjugates comprising heparin conjugated to a peptide that binds to a protein of the extracellular matrix (ECM) of cellular tissue, such as a collagen-binding peptide that binds to collagen of the ECM. The disclosed heparin conjugates may be utilized in methods that include treating ECM material to incorporate the heparin conjugates and impart anticoagulant activity to the ECM. The disclosed heparin conjugates also may be formulated as pharmaceutical compositions for treating and/or preventing vascular injuries and conditions.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: July 16, 2024
    Assignee: Northwestern University
    Inventors: Guillermo A. Ameer, Jason A. Wertheim, Bin Jiang, Kyle Koss
  • Patent number: 12029798
    Abstract: The present invention provides a method of targeted molecular imaging and/or targeted drug delivery, wherein two components or probes each interacts with one or more biomarkers on a cell and separately interact with each other to form a stable bond, such as a stable covalent bond. In certain non-limiting embodiments, at least one of the probes is photo-triggered to allow for bonding with at least one second probe. In certain non-limiting embodiments, the cell is a tumor or cancer cell. The present invention also relates to compounds, probes, and kits for use in targeted molecular imaging and/or targeted drug delivery.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 9, 2024
    Inventors: Dexing Zeng, Lingyi Sun, Yongkang Gai
  • Patent number: 12029796
    Abstract: Fluorescent probes for silver ion detection include organic, water-soluble compounds having aggregation-induced emission (AIE) characteristics. The probes can sense or detect silver ions through aggregation or a precipitation reaction between the silver ions and the organic compounds which induces fluorescence. The compounds are acidic, soluble in aqueous phase, and provide low background fluorescence in aqueous solutions.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: July 9, 2024
    Inventors: Benzhong Tang, Sijie Chen, Sheng Xie, Wenxiong Wang, Neng Yan, Alex Yu Hin Wong
  • Patent number: 12023387
    Abstract: Small molecule compounds having aggregation-induced emission (AIE) characteristics include donor-acceptor (D-A) structural NIR fluorophores based on 1,3-bis(dicyanomethylene)indan (BDCI), a strong and steric electron-deficient acceptor. A twisted quasi-double bond (TQDB) links each electron donor with the acceptor. The compounds can be used as NIR-II fluorescent dyes for in vivo imaging. The compounds can conjugate with bioactive molecules, such as peptides, sugars, aptamers and antibodies, to provide specific and active NIR-II fluorescent probes. The compounds can serve as active NIR-II fluorescent probes in many applications, such as, cancer cell-targeted imaging, accurate diagnosis of disease, and image-guided phototherapy.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: July 2, 2024
    Inventors: Benzhong Tang, Pengfei Zhang, Jen-Shyang Ni
  • Patent number: 12016935
    Abstract: Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: June 25, 2024
    Assignee: Washington University
    Inventors: Yongjian Liu, Robert Gropler, Steven Brody, Daniel Kreisel
  • Patent number: 11987604
    Abstract: A fusion protein, a nanoparticle composed by a plurality of monomers of said fusion protein, and uses thereof. A fusion protein based on the heavy chain of human ferritin is de-scribed, which includes at the N terminus of the protein at least one metalloproteinase cleavage sequence and a modified PAS polypeptide that acts as a masking polymer that in-creases the protein drug stability, as well as a nanoparticle composed of multiple monomers of said fusion protein, a nucleic acid encoding for said fusion protein, and diagnostic and therapeutic applications thereof.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: May 21, 2024
    Assignee: THENA BIOTECH S.R.L.
    Inventor: Aldo Braca
  • Patent number: 11975074
    Abstract: A method of treating a PSMA expressing cancer in a subject includes (a) administering to the subject a PSMA-targeted phthalocyanine conjugate compound having the formula (I), (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject, (c) surgical resection of the detected cancer, and (d) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 7, 2024
    Inventor: James Basilion
  • Patent number: 11970554
    Abstract: Disclosed are 13N-oxytocin molecules, methods of manufacture of 13N-oxytocin molecules and methods of use of 13N-oxytocin molecules in the determination of the distribution and kinetics of 13N-oxytocin molecules after craniofacial or other application methods.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 30, 2024
    Inventors: Steen Jakobsen, Michael Winterdahl, Erik Nguyen Nielsen, David C. Yeomans, Dean Carson
  • Patent number: 11969484
    Abstract: The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: April 30, 2024
    Assignee: Ariceum Therapeutics GmbH
    Inventors: Marie Delporte, Sabine Hovest, Jens Kaufmann, Dennis Mewis, Anne Petit, Joel Richard
  • Patent number: 11944691
    Abstract: The present disclosure relates to imaging and endoradiotherapy of diseases involving chemokine receptor 4 (CXCR4). Provided are compounds which bind or inhibit hCXCR4 and mCXCR4 and furthermore carry at least one moiety which is amenable to labeling. Provided are also medical uses of such compounds.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: April 2, 2024
    Inventors: Theresa Osl, Hans-Jürgen Wester, Margret Schottelius, Tobias Kapp, Horst Kessler
  • Patent number: 11938199
    Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: March 26, 2024
    Inventors: Yves-Louis Janin, Eloi Paul Coutant, Vincent Hervin, Glwadys Gagnot, Yves Jacob, Sophie Goyard, Thierry Rose
  • Patent number: 11919972
    Abstract: Disclosed are peptides having non-canonical amino acids. These peptides are useful, for example, as protein binding agents. Libraries of such peptides can be used, for example to screen and select protein binding agents. The broader chemical space of the disclosed peptides can provide peptide with different, improved, more specific, and/or pharmaceutically compatible peptides and protein binding agents. In some forms, the peptides can have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: March 5, 2024
    Inventor: Anders Eliasen
  • Patent number: 11890348
    Abstract: The invention described herein relates to methods and compositions for treating cancer in a patient, or a tumor cell, by administering an effective amount of an antibody-anti-fugetactic agent complex.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: February 6, 2024
    Assignee: The General Hospital Corporation
    Inventor: Mark C. Poznansky
  • Patent number: 11872311
    Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: January 16, 2024
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie Kramer, Christopher Y. Poon
  • Patent number: 11871895
    Abstract: The present invention provides a targeted nanoplex platform for in vivo imaging and theranostic imaging of cancer to simultaneously provide non-invasive assessment of tumor burden and cancer-selective treatments.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: January 16, 2024
    Inventors: Ming Li, Ishan Barman, Martin Pomper, Sangeeta Ray
  • Patent number: 11866457
    Abstract: It is an object of the present invention to provide a clearing agent, by which after a fusion of the streptavidin mutant and a molecular probe has been administered, the fusion, which is not localized in a target site such as an affected site but remains in the body, can be promptly removed (cleared) from the body. The present invention provides a compound represented by the following formula (1) or a salt thereof: wherein X1a, X1b, X2a and X2b each independently represent O or NH; Y1 and Y2 each independently represent C or S; Z1 and Z2 each independently represent O, S or NH; V1 and V2 each independently represent S or S+—O?; n1 and n2 each independently represent an integer of 0 or 1; L10 and L12 each independently represent a divalent linking group; L11 represents a trivalent linking group; L14 represents a divalent linking group; and Sugar represents a sugar residue.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: January 9, 2024
    Inventor: Masanobu Tsukagoshi
  • Patent number: 11865195
    Abstract: The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: January 9, 2024
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Albert J. Sinusas, Joseph G. Akar, Richard R. Cesati, Heike S. Radeke, Stephen B. Haber
  • Patent number: 11857648
    Abstract: The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 2, 2024
    Inventors: Dexing Zeng, Lingyi Sun, Yongkang Gai
  • Patent number: 11858993
    Abstract: Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: January 2, 2024
    Assignees: Memorial Sloan Kettering Cancer Center, Massachusetts Institute of Technology
    Inventors: Sarah Cheal, Hong Xu, Steven Larson, Nai-Kong Cheung, Karl Dane Wittrup, Alice Tzeng
  • Patent number: 11850216
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: December 26, 2023
    Assignees: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher